Browse by People


Up a level
Export as [feed] RSS [feed] RSS 2.0 Short Author List
Number of items: 5.


Liu, Xinxue, Wright, Annie, Feng, Shuo, Janani, Leila, Aley, Parvinder K, Babbage, Gavin, Baker, Jonathan, Baxter, David, Bawa, Tanveer, Bula, Marcin
et al (show 50 more authors) (2023) Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial. JOURNAL OF INFECTION, 87 (1). pp. 18-26.


Liu, Xinxue, Munro, Alasdair PS, Feng, Shuo, Janani, Leila, Aley, Parvinder K, Babbage, Gavin, Baxter, David, Bula, Marcin, Cathie, Katrina, Chatterjee, Krishna
et al (show 48 more authors) (2022) Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial. JOURNAL OF INFECTION, 84 (6). pp. 795-813.


Liu, Xinxue, Munro, Alasdair PS, Feng, Shuo, Janani, Leila, Aley, Parvinder K, Babbage, Gavin, Baxter, David, Bula, Marcin, Cathie, Katrina, Chatterjee, Krishna
et al (show 48 more authors) (2023) Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial (vol 84, pg 795, 2022). JOURNAL OF INFECTION, 86 (5). pp. 540-541.


Munro, Alasdair PS, Janani, Leila, Cornelius, Victoria, Aley, Parvinder K, Babbage, Gavin, Baxter, David, Bula, Marcin, Cathie, Katrina, Chatterjee, Krishna, Dodd, Kate
et al (show 44 more authors) (2021) Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. LANCET, 398 (10318). pp. 2258-2276.


Munro, Alasdair PS, Feng, Shuo, Janani, Leila, Cornelius, Victoria, Aley, Parvinder K, Babbage, Gavin, Baxter, David, Bula, Marcin, Cathie, Katrina, Chatterjee, Krishna
et al (show 45 more authors) (2022) Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. LANCET INFECTIOUS DISEASES, 22 (8). pp. 1131-1141.

This list was generated on Sat Feb 10 12:44:49 2024 GMT.